Showing 111-120 of 9753 results for "".
Indiana Gets SUNucated, Dr. Joel Cohen Honored, Rosacea Awareness
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-indiana-gets-sunucated-dr-joel-cohen-honored-rosacea-awareness/18317/Indiana is the first state in 2018 to give children broader access to sunscreen at school through the SUNucation Initiative. The Indiana Academy of Dermatology, with a grant from the American Society for Dermatologic Surgery Association, helped successfully pass the legislation. Joel L. Cohen, MD ofDermoscopy Pearls
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermoscopy-pearls/19985/Steven Q. Wang discusses some of the challenges of managing patients with melanoma, the importance of early diagnosis without performing too many biopsies, and the pitfalls of specific lesions, including featureless, small, and collision lesions.Insights on Care for Skin of Color, Part 1
https://practicaldermatology.com/topics/skin-of-color/insights-on-care-for-skin-of-color-part-1/18184/The full spectrum of skin phototypes means that there is no "typical presentation" of skin disease. Host Neal Bhatia, MD speaks with James Q. Del Rosso, DO and Hilary Baldwin, MD about patients' needs during isolation and beyond.Derm Insider: Ethics and Industry: How to Manage Relationships with Pharma
https://practicaldermatology.com/topics/practice-management/derm-insider-ethics-and-industry-how-to-manage-relationships-with-pharma/19029/In this edition, host Neal Bhatia, MD and guests Tom Prunty and James Q. Del Rosso, DO tackle the ethics of industry relationships. They discuss the nuances and challenges of physicians fostering appropriate relationships with pharmaceutical manufacturers amid an increasingly stringent regulatory laCosmetic Benefits and Post-Treatment
https://practicaldermatology.com/series/pdt-in-practice/cosmetic-benefits-and-post-treatment/29117/Dr. Joel L. Cohen describes the cosmetic benefits of photodynamic therapy and the post-treatment considerations involved.Patient Experience with PDT
https://practicaldermatology.com/series/pdt-in-practice/patient-experience-pdt/28863/Dr. Joel L. Cohen discusses how he implemented photodynamic therapy and describes the patient experience with it, including scheduling considerations.Enstilar Approved; New Data for Otezla, Duac
https://practicaldermatology.com/topics/psoriasis/dermwiretv-enstilar-approved-new-data-for-otezla-duac/18687/LEO Pharma's Enstilar (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% has been FDA-approved for plaque psoriasis. New data presented at EADV on Stiefel's Duac, Celgene's Otezla, and Boehringer Ingelheim's investigational biologic compound BI 655066. Plus, Galderma's OTC Excipial lSDPA: Sara Wilchowski Talks About Transitioning to Industry and Understanding How Nutraceuticals Can Help Patients
https://practicaldermatology.com/conferences/sdpa-2024/sdpa-sara-wilchowski-talks-about-transitioning-to-industry-and-understanding-how-nutraceuticals-can-help-patients/29513/At the SDPA 22nd Annual Fall Dermatology Conference, Practical Dermatology caught up with Sara Wilchowski, DMSc, MPAS, PA-C. Wilchowski is currently a senior medical science liaison and joined a panel of MSLs to discuss the ins and outs of transitioning to industry. Following the panel, she gave a lNon-Biologics in Treatment and Management of Prurigo Nodularis
https://practicaldermatology.com/programs/dermatology-hub-neuroimmune-network/non-biologics-in-treatment-and-management-of-prurigo-nodularis/48785/James Q. Del Rosso, DO, FAOCD, discusses the utility of topical therapies, cleansers, moisturizers, and phototherapy in treatment and management of prurigo nodularis.The Resurgence of Ablative Devices
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/the-resurgence-of-ablative-devices/18620/E. Victor Ross, MD, talks to host Joel L. Cohen, MD about the resurgence of traditional ablative devices. Dr. Ross says he never abandoned full-face CO2 resurfacing, but explains the key is to titrate the settings down—doing confluent 100 percent coverage but low-depth one pass on the forehead and c